Jenny Robertson - 14 Mar 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Legal Officer
Signature
/s/ Youjin Choi, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
14 Mar 2025
Net transactions value
+$14,929
Form type
4
Filing time
09 Apr 2025, 17:46:09 UTC
Previous filing
21 Feb 2025
Next filing
20 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $14,929 +5,720 +9.9% $2.61 63,619 14 Mar 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 Includes 54,062 restricted stock units.